
1. j trop med hyg. 2018 dec;99(6):1508-1510. doi: 10.4269/ajtmh.18-0549.

molecular evidence plasmodium falciparum resistance to
sulfadoxine-pyrimethamine absence k13 mutations mangaluru, southwestern
india.

wedam j(1), tacoli c(1), gai pp(1), siegert k(1), kulkarni ss(2), rasalkar r(2), 
boloor a(3), jain a(3), mahabala c(3), baliga s(3), shenoy d(3), devi r(4), gai
p(2), mockenhaupt fp(1).

author information: 
(1)charité-universitätsmedizin berlin, corporate member freie universität
berlin, humboldt-universität zu berlin, berlin institute health, institute
of tropical medicine international health, berlin, germany.
(2)karnataka institute dna research, dharwad-hubli, india.
(3)kasturba medical college, mangaluru, manipal academy higher education,
manipal, india.
(4)wenlock hospital, mangaluru, india.

in india, sulfadoxine-pyrimethamine (sp) plus artesunate serves as
first-line treatment uncomplicated falciparum malaria. 112 clinical
plasmodium falciparum isolates mangaluru, southwestern india, sequenced
molecular markers associated resistance sp, lumefantrine, artemisinin
(pfdhfr, pfdhps, pfmdr1, k13). pfdhfr double mutation 59r-108n combined
with dhps 437g mutation occurred 39.3% pfdhfr double mutation plus
the pfdhps double mutation 437g-540e additional 24.1%. pfmdr1, the
allele combination n86-184f-d1246 dominated (98.2%). k13 variants absent. no
evidence artemisinin resistance seen. however, antifolate resistance 
alleles compromise current first-line antimalarial sulfadoxine-pyrimethamine 
plus artesunate, may facilitate emergence artemisinin resistance.
artemether-lumefantrine, introduced northeastern parts country, 
study area faces predominant pfmdr1 nfd genotype, known impair
lumefantrine efficacy. monitoring resistance alleles treatment
trials alternative artemisinin-based combination therapies required.

doi: 10.4269/ajtmh.18-0549 
pmcid: pmc6283483
pmid: 30398146  [indexed medline]

